Medivolve Inc.

Medivolve Inc.

MEDVF
Medivolve Inc.US flagOther OTC
0.00
USD
- -
- -
2,702.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
-0.07
1.59
4.49
0.05
0.03
0.03
Basic EPS, GAAP
-4.88
-7.48
-7.19
-4.54
-2.48
-0.59
1.39
-0.31
-1.19
-5.66
-0.34
-0.68
-0.61
-0.54
Free Cash Flow per Basic Share
-2.97
-6.93
-5.82
-1.41
-0.37
-0.84
1.52
-0.2
-1.08
-1.71
-0.43
0.22
-0.12
-0.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-19.24
-33.92
-39.45
-37.46
-39.24
-14.44
1.59
1.77
0.7
-2.07
0.31
-0.36
-0.94
-0.94
Tangible Book Value per Share
34.5
12.41
5.2
1.4
-1.1
1.62
2.31
1.99
0.87
-1.91
0.8
-0.04
-0.61
-0.65
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
2
2
2
7
19
27
27
27
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
11
87
1
1
1
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1,693.86
-80.79
15.79
-944.4
-491.38
-387.59
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
5
2
- -
- -
Net Income, GAAP
-2
-3
-3
-2
-1
-1
3
-1
-3
-38
-7
-18
-16
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1,787.07
-356.96
-7.61
-1,322.72
-2,397.53
-1,572.02
Working Capital
6
3
1
- -
-1
1
5
4
2
-24
15
-1
-17
-18
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
Total Equity
13
5
2
1
-1
2
5
5
2
-10
18
- -
-16
-17
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-108.77
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-42.32
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
-18.58
-96.92
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'23
Dec'23
Mar'24
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
2
- -
- -

Working Capital

FRC

in mil. unless spec.
Sep'23
Dec'23
Mar'24
Total Current Assets
9
1
1
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
7
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
17
18
19
Payables & Accruals
15
15
16
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-666.28%
-1,206.55%
-4,995.77%
Free Cash Flow
30.03%
89.66%
-151.83%
Net Income, GAAP
90.49%
331.34%
-10.39%
Sales/Revenue/Turnover
- -
- -
-50.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
17
9
- -
5
1
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.05
-0.22
-0.26
- -
-0.68
2023
-0.11
-0.06
-0.13
- -
-0.61
2024
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Neil Said
Full Time Employees
25
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
65 Queen Street West Toronto ON Canada M5H 2M5
IPO Date
Dec 18, 2009
Business
Medivolve Inc. operates as a healthcare technology and services provider. The company concentrates on innovative solutions within telehealth, clinical diagnostics, and artificial intelligence-powered healthcare management. Medivolve Inc., previously known as QuestCap Inc., originated in 2005 and maintains its headquarters in Toronto, Canada.

Company News

APIChatGPT
  • Medivolve Announces Management Changes

  • Medivolve Announces Change of Auditor

  • Medivolve announces telehealth platform development contract; management and director changes

  • Medivolve Announces Telehealth Platform Development Contract and Change of Officers and Directors

  • Medivolve Announces Change of Auditor and Board Changes

  • Medivolve Announces Board Changes

  • Medivolve establishes a management services organization in Puerto Rico

  • Medivolve closes previously announced secured convertible note financing for aggregate gross proceeds of $1.2M